beta-lapachone has been researched along with Cancer of Lung in 17 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to investigate the effect of beta-lapachone, a quinone obtained from the bark of the lapacho tree (Tabebuia avellanedae), on the cell growth and apoptosis in human lung carcinoma cell line A549." | 7.73 | Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity. ( Choi, YH; Woo, HJ, 2005) |
| " In the second part, we found that the FDA-approved non-steroidal anti-inflammatory drug sulindac and its metabolites, sulindac sulfide and sulindac sulfone, increased NQO1 expression and activity in the lung adenocarcinoma cell lines CL1-1 and CL1-5, which have lower NQO1 levels and lower sensitivity to β-lapachone treatment than the A549 cell lines, and that inhibition of NQO1 by either dicoumarol treatment or NQO1 siRNA knockdown inhibited this sulindac-induced increase in β-lapachone cytotoxicity." | 3.80 | Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells. ( Chau, YP; Kung, HN; Liu, YL; Lu, KS; Weng, TY, 2014) |
| "The objective of the present study was to investigate the effect of beta-lapachone, a quinone obtained from the bark of the lapacho tree (Tabebuia avellanedae), on the cell growth and apoptosis in human lung carcinoma cell line A549." | 3.73 | Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity. ( Choi, YH; Woo, HJ, 2005) |
| "However, the effect of β-lapachone on metastasis of melanoma cells is unclear." | 1.46 | β-Lapachone suppresses the lung metastasis of melanoma via the MAPK signaling pathway. ( Han, YH; Hong, SH; Kee, JY; Kim, DS; Mun, JG; Park, R; Park, SH; Park, SJ; So, HS; Um, JY, 2017) |
| "Lung cancer is one of the most lethal forms of cancer and current chemotherapeutic strategies lack broad specificity and efficacy." | 1.42 | Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. ( Boothman, DA; Gao, J; Hammer, S; Huang, G; Huang, X; Kilgore, JA; Ma, X; Moore, Z; Wang, Y; Williams, NS, 2015) |
| "Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) is the most common pathological type with a reported frequency of about 85% of all cases." | 1.42 | Beta-Lapachone Suppresses Non-small Cell Lung Cancer Proliferation through the Regulation of Specificity Protein 1. ( Bang, W; Chae, JI; Choi, YH; Jeon, YJ; Shim, JH, 2015) |
| "4) or in 1 M sodium salicylate, which agrees with the desired dosing sequence of the two drugs to exert synergistic pharmacologic effect at different cell checkpoints." | 1.42 | β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. ( Chen, Z; Gao, J; Liu, C; Qian, F; Yang, K; Zhang, L, 2015) |
| "Lung cancer is the leading cause of cancer-related deaths with current chemotherapies lacking adequate specificity and efficacy." | 1.36 | Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. ( Bey, EA; Blanco, E; Boothman, DA; Bornmann, WG; Carnevale, KA; Chen, H; Gao, J; Kessinger, CW; Khemtong, C; Setti-Guthi, J; Yang, SG, 2010) |
| "Lung cancer is the number one cause of cancer-related deaths in the world." | 1.34 | An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. ( Bentle, MS; Bey, EA; Boothman, DA; Bornmann, WG; Dong, Y; Gao, J; Girard, L; Minna, JD; Reinicke, KE; Yang, CR, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Bey, EA | 3 |
| Bentle, MS | 1 |
| Reinicke, KE | 1 |
| Dong, Y | 3 |
| Yang, CR | 1 |
| Girard, L | 1 |
| Minna, JD | 2 |
| Bornmann, WG | 2 |
| Gao, J | 4 |
| Boothman, DA | 5 |
| Li, X | 3 |
| Bian, J | 2 |
| Wang, N | 1 |
| Qian, X | 1 |
| Gu, J | 1 |
| Mu, T | 1 |
| Fan, J | 1 |
| Yang, X | 1 |
| Li, S | 1 |
| Yang, T | 1 |
| Sun, H | 1 |
| You, Q | 3 |
| Zhang, X | 3 |
| Wu, X | 2 |
| Li, Z | 1 |
| Yu, Y | 1 |
| Torrente, L | 1 |
| Prieto-Farigua, N | 1 |
| Falzone, A | 1 |
| Elkins, CM | 1 |
| Haura, EB | 1 |
| DeNicola, GM | 1 |
| Kee, JY | 2 |
| Han, YH | 2 |
| Kim, DS | 2 |
| Mun, JG | 2 |
| Park, SH | 1 |
| So, HS | 1 |
| Park, SJ | 2 |
| Park, R | 1 |
| Um, JY | 2 |
| Hong, SH | 2 |
| Kung, HN | 1 |
| Weng, TY | 1 |
| Liu, YL | 1 |
| Lu, KS | 1 |
| Chau, YP | 1 |
| Ma, X | 1 |
| Huang, X | 2 |
| Moore, Z | 1 |
| Huang, G | 1 |
| Kilgore, JA | 2 |
| Wang, Y | 1 |
| Hammer, S | 1 |
| Williams, NS | 2 |
| Jeon, YJ | 1 |
| Bang, W | 1 |
| Choi, YH | 2 |
| Shim, JH | 1 |
| Chae, JI | 1 |
| Zhang, L | 1 |
| Chen, Z | 1 |
| Yang, K | 1 |
| Liu, C | 1 |
| Qian, F | 1 |
| Park, J | 1 |
| Ahn, KS | 1 |
| Kim, HJ | 1 |
| Motea, EA | 1 |
| Moore, ZR | 1 |
| Yao, J | 1 |
| Chakrabarti, G | 1 |
| Silvers, MA | 1 |
| Patidar, PL | 1 |
| Cholka, A | 1 |
| Fattah, F | 1 |
| Cha, Y | 1 |
| Anderson, GG | 1 |
| Kusko, R | 1 |
| Peyton, M | 1 |
| Yan, J | 1 |
| Xie, XJ | 1 |
| Sarode, V | 1 |
| Beg, M | 1 |
| Gerber, DE | 1 |
| Jeong, SY | 1 |
| Yoon, SM | 1 |
| Jung, J | 1 |
| Woo, HN | 1 |
| Yi, SL | 1 |
| Song, SY | 1 |
| Park, HJ | 3 |
| Kim, C | 2 |
| Lee, JS | 2 |
| Choi, EK | 2 |
| Dong, GZ | 1 |
| Oh, ET | 1 |
| Lee, H | 1 |
| Park, MT | 1 |
| Song, CW | 2 |
| Blanco, E | 1 |
| Khemtong, C | 1 |
| Yang, SG | 1 |
| Setti-Guthi, J | 1 |
| Chen, H | 1 |
| Kessinger, CW | 1 |
| Carnevale, KA | 1 |
| Woo, HJ | 1 |
| Chae, JJ | 1 |
| Hwang, TS | 1 |
| Lim, BU | 1 |
17 other studies available for beta-lapachone and Cancer of Lung
| Article | Year |
|---|---|
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Human | 2007 |
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Lung; Lung Neoplasms; Mice; Mice, Nude; Mo | 2016 |
2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferat | 2017 |
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug R | 2018 |
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance | 2020 |
β-Lapachone suppresses the lung metastasis of melanoma via the MAPK signaling pathway.
Topics: Animals; Female; Humans; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Mice; Mice, Inbred C | 2017 |
Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agen | 2014 |
Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Comet Assay; Eryth | 2015 |
Beta-Lapachone Suppresses Non-small Cell Lung Cancer Proliferation through the Regulation of Specificity Protein 1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, | 2015 |
β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, N | 2015 |
β-Lapachone Inhibits Lung Metastasis of Colorectal Cancer by Inducing Apoptosis of CT26 Cells.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prol | 2017 |
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Da | 2016 |
Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization.
Topics: Animals; Antibodies, Monoclonal; Biological Transport; Cell Line, Tumor; Cell Survival; Chemistry, P | 2009 |
Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB.
Topics: Antigens, Differentiation; Cell Line, Tumor; Cell Survival; Cyclin D1; Humans; I-kappa B Kinase; Lun | 2010 |
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Fem | 2010 |
Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity.
Topics: Apoptosis; Carcinoma; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; Humans; | 2005 |
Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Fib | 2008 |